Celldex Therapeutics (CLDX) Insider Trading & Ownership $27.02 +0.80 (+3.05%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Celldex Therapeutics (NASDAQ:CLDX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$308,430.00Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$9.16 M Get CLDX Insider Trade Alerts Want to know when executives and insiders are buying or selling Celldex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CLDX Insider Buying and Selling by Quarter Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Celldex Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/11/2024Anthony S MarucciCEOBuy11,500$26.82$308,430.00 6/14/2024Elizabeth CrowleyVPSell30,000$34.87$1,046,100.00 6/14/2024Samuel Bates MartinCFOSell17,172$35.42$608,232.24 6/7/2024Diane C YoungSVPSell45,000$35.26$1,586,700.00 6/7/2024Elizabeth CrowleyVPSell15,000$35.06$525,900.00 6/3/2024Richard M WrightVPSell46,844$33.72$1,579,579.68 5/30/2024Elizabeth CrowleyVPSell38,597$33.64$1,298,403.08 5/30/2024Margo Heath-ChiozziSVPSell38,719$34.07$1,319,156.33 5/30/2024Samuel Bates MartinCFOSell35,000$34.05$1,191,750.00 (Data available from 1/1/2013 forward) CLDX Insider Trading Activity - Frequently Asked Questions Who is on Celldex Therapeutics's Insider Roster? The list of insiders at Celldex Therapeutics includes Anthony S Marucci, Diane C Young, Elizabeth Crowley, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, and Sarah Cavanaugh. Learn more on insiders at CLDX. What percentage of Celldex Therapeutics stock is owned by insiders? 3.80% of Celldex Therapeutics stock is owned by insiders. Learn more on CLDX's insider holdings. Which Celldex Therapeutics insiders have been buying company stock? The following insider purchased CLDX shares in the last 24 months: Anthony S Marucci ($308,430.00). How much insider buying is happening at Celldex Therapeutics? Insiders have purchased a total of 11,500 CLDX shares in the last 24 months for a total of $308,430.00 bought. Which Celldex Therapeutics insiders have been selling company stock? The following insiders have sold CLDX shares in the last 24 months: Diane C Young ($1,586,700.00), Elizabeth Crowley ($2,870,403.08), Margo Heath-Chiozzi ($1,319,156.33), Richard M Wright ($1,579,579.68), and Samuel Bates Martin ($1,799,982.24). How much insider selling is happening at Celldex Therapeutics? Insiders have sold a total of 266,332 Celldex Therapeutics shares in the last 24 months for a total of $9,155,821.33 sold. Celldex Therapeutics Key ExecutivesMr. Anthony S. Marucci M.B.A. (Age 62)Founder, President, CEO & Director Compensation: $1.27M1 recent tradesDr. Tibor Keler Ph.D. (Age 65)Founder, Chief Scientific Officer & Executive VP Compensation: $810.39kMr. Sam Martin (Age 53)Senior VP, CFO, Secretary & Treasurer Compensation: $676.87kDr. Margo Heath-Chiozzi M.D. (Age 67)Senior Vice President of Regulatory Affairs Compensation: $667.21kDr. Diane C. Young M.D. (Age 67)Senior VP & Chief Medical Officer Compensation: $696.45kProf. Joseph P. Schlessinger Ph.D. (Age 79)Co-Founder & Member of Scientific Advisory Board Ms. Sarah Cavanaugh (Age 49)Senior Vice President of Corporate Affairs & Administration Mr. Freddy A. Jimenez Esq. (Age 55)Senior VP & General Counsel Compensation: $579.7kDr. Ronald A. Pepin (Age 68)Chief Business Officer & Senior VP Compensation: $441.84kMs. Elizabeth Crowley (Age 52)Chief Product Development Officer & Senior VP Compensation: $507.24k3 recent trades More Insider Trading Tools from MarketBeat Related Companies NTLA Insider Transactions NEOG Insider Transactions AWH Insider Transactions RIOT Insider Transactions HALO Insider Transactions IONS Insider Transactions ALKS Insider Transactions FOLD Insider Transactions GERN Insider Transactions LGND Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:CLDX) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
